由千岛湖饮用天然水"云上天泉"冠名播出的《Hi，老板》，最新一期约到了盘龙药业董事长谢晓林。29 岁那年，他借高利贷、卖祖屋，承包下难以为继的小药厂。在他的带领下，当初的小药厂如今成长为中 医药标杆企业。昔日秦岭采药少年，直言老板永远是打工的，要为社会创造价值。本期《Hi，老板》， 我们在秦岭脚下、西安古城，与盘龙药业董事长谢晓林聊了聊。 以下是我们的对话，更多内容请关注"证券时报"官方视频号、抖音号置顶视频及《Hi，老板》专辑。 于德江：公司上市八年了，财富数字在屏幕上跳动，您自己有没有一些感触？ 谢晓林：我不看数字，但是我也关心数字，这个数字是市场给予我们投资者的一个预期，是不是达到。 对我个人来讲，这个财富，我觉得不重要。到现在我也没有减持，还要加大我自己的投入。我自己有信 心，肯定投资者对公司也有信心。 于德江：您小时候有没有想过现在会成就这样一番事业。 谢晓林：没想到。我是高中一毕业就到这个西安药厂柞水分厂，在药厂之后我又参加了高考。先工作参 加高考，然后又到陕西财经学院学习，毕业了之后，1989年选择继续回到西安药厂柞水分厂工作。 于德江：您大学毕业时候是不是也有别的选择，不一定要回到这个小厂来。 ...

Core Viewpoint - The investment sentiment around Pian Zai Huang remains strong despite recent poor financial performance, as notable investor Lin Yuan continues to hold his shares, indicating confidence in the company's long-term value [1][7]. Financial Performance - For the first three quarters of 2025, Pian Zai Huang reported revenue of 7.442 billion yuan, a year-on-year decline of 11.93% [1][7]. - The net profit attributable to shareholders for the same period was 2.129 billion yuan, down 20.74% year-on-year [1][7]. - The third quarter alone saw revenue drop to 2.064 billion yuan, a decrease of 26.28%, with net profit falling to 687 million yuan, down 28.82% [2][8]. Inventory and Cash Flow - As of the latest report, inventory increased to 6.16 billion yuan, reflecting a growth of 24.02% since the beginning of the year [1][7]. - The cash flow from operating activities showed a significant decline, with a drop of 62.53% year-on-year [9]. Market Valuation - The market capitalization of Pian Zai Huang peaked at over 290 billion yuan in 2021 but has since fallen to approximately 101.1 billion yuan, representing a loss of about 188.9 billion yuan [9][11]. - The stock price has decreased by over 60% from its peak, currently standing at 167.53 yuan per share [9][11]. Product Pricing - The price of Pian Zai Huang's medicinal products has significantly decreased, with the price of a 3g pill dropping to between 614 yuan and 760 yuan, reflecting a reduction of over 15% from the official retail price [5][11].

Group 1 - The core viewpoint is that Lin Yuan, a well-known investor, remains optimistic about Pien Tze Huang, stating that it is a valuable product that is hard to find, and he has no intention of selling his shares [1][2] - Lin Yuan has been holding Pien Tze Huang shares since 2005 and believes that the product could eventually reach prices comparable to two bottles of Moutai [1] - Pien Tze Huang's recent financial performance has shown significant declines, with a revenue of 7.442 billion yuan for the first three quarters of 2025, down 11.93% year-on-year, and a net profit of 2.129 billion yuan, down 20.74% year-on-year [2] Group 2 - In Q3 2025, Pien Tze Huang reported a revenue of 2.064 billion yuan, a decrease of 26.28% year-on-year, and a net profit of 687 million yuan, down 28.82% year-on-year [3] - The company's stock price has been under pressure, with its market value dropping from a peak of 290 billion yuan in 2021 to 101.1 billion yuan as of December 9, 2025, representing a loss of over 60% [5] - The price of Pien Tze Huang's product has significantly decreased, with the retail price for a 3g tablet dropping to between 614 yuan and 760 yuan, reflecting a decline of over 15% from the official retail price [7]

证券代码：603896 证券简称：寿仙谷 公告编号：2025-077 债券代码：113660 债券简称：寿22转债 浙江寿仙谷医药股份有限公司 关于举办2025年第二次投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药股份有限公司（以下简 称"公司"或"寿仙谷"）情况，公司拟举办2025年第二次投资者接待日活动，现将有关事项公告如下： 1、接待时间：2025年12月23日8:50-17:00 2、接待地点：公司基地一寿仙谷有机国药养生园；公司总部一浙江省武义县黄龙三路12号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李振宇、董事兼副总经理林荣 志、董事兼副总经理徐靖、董事黄俊华、副总经理兼董事会秘书刘国芳、财务负责人祝彪、副总经理王 汉波、投资者服务部总监曹秀娟（如遇特殊情况，参会人员会有所调整） 4、活动日程： ■ 注：①投资者可根据自己的行程选择合适的集合地点，公司将统一安排车辆前往基地参观；自驾的投资 者可以将 ...

Core Viewpoint - The prominent investor Lin Yuan remains optimistic about the stock of Pian Zai Huang, stating that it is a valuable product that is hard to find, despite the company's recent poor financial performance [2]. Financial Performance - For the first three quarters of 2025, Pian Zai Huang reported revenue of 7.442 billion yuan, a year-on-year decline of 11.93% [2][3]. - The net profit attributable to shareholders was 2.129 billion yuan, down 20.74% year-on-year [2][3]. - In Q3 2025, the company achieved revenue of 2.064 billion yuan, a decrease of 26.28% compared to the same quarter last year, with a net profit of 687 million yuan, down 28.82% year-on-year [2][3]. Inventory and Market Value - The inventory increased to 6.16 billion yuan, reflecting a growth of 24.02% since the beginning of the year [2]. - The market value of Pian Zai Huang has significantly decreased, with its stock price dropping over 60% from its peak in 2021, resulting in a total market value of 101.1 billion yuan as of December 9, 2025 [3][4]. Product Pricing - The price of Pian Zai Huang's medicinal pills has dropped significantly, with current retail prices ranging from 614 yuan to 760 yuan, representing a decline of over 15% from the official retail price [4].

Group 1 - The core viewpoint of the article highlights the ongoing commitment of investor Lin Yuan to Pianzaihuang stock, despite recent poor financial performance [1][4] - Lin Yuan has been a shareholder since 2005 and believes Pianzaihuang is a unique product with significant market potential, comparing its future price to that of premium liquor [1][2] - The latest financial report from Pianzaihuang shows a revenue of 7.442 billion yuan for the first three quarters of 2025, a year-on-year decline of 11.93%, and a net profit of 2.129 billion yuan, down 20.74% [1][2] Group 2 - In Q3 2025, Pianzaihuang reported a revenue of 2.064 billion yuan, a decrease of 26.28%, and a net profit of 688 million yuan, down 28.82% [2] - The company's stock price has significantly declined, with a market value dropping from over 290 billion yuan in 2021 to 101.1 billion yuan as of December 9, 2025, representing a loss of approximately 188.9 billion yuan [4] - Pianzaihuang's inventory has increased to 6.16 billion yuan, a rise of 24.02% since the beginning of the year, indicating potential challenges in sales [1]

广誉远（600771.SH）12月9日在投资者互动平台表示，您好，感谢您的关注。公司产品龟龄集（30 粒）的官方指导零售价为598元/盒，公司并未对其进行调整。线上店铺销售价格受平台活动政策、满减 优惠及新人福利等多项因素影响，价格在合理区间内波动属正常情况。 每经AI快讯，有投资者在投资者互动平台提问：请问龟龄集（30粒）官方市场指导零售价是多少一 盒？微店广誉远大健康商城销售价为528元/盒，请问最近销售价是否提价了？ （记者 曾健辉） ...

Group 1 - The stock of Tailong Pharmaceutical (600222) fell by 4.43% today, with a turnover rate of 23.90% and a trading volume of 1.146 billion yuan, experiencing a fluctuation of 22.28% [2] - The stock was listed on the Shanghai Stock Exchange due to its daily fluctuation value reaching 22.28%, with a total net selling of 40.72 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 170 million yuan, with a buying amount of 64.49 million yuan and a selling amount of 105 million yuan, resulting in a net selling of 40.72 million yuan [2] Group 2 - The largest buying brokerage was Guotai Junan Securities Headquarters, with a buying amount of 19.26 million yuan, while the largest selling brokerage was Yuekai Securities Shenzhen Shennan Avenue, with a selling amount of 25.70 million yuan [2] - The stock experienced a net outflow of 191 million yuan from main funds today, including a net outflow of 104 million yuan from large orders and 86.37 million yuan from big orders, with a total net outflow of 191 million yuan over the past five days [2] - The company reported its third-quarter results on October 30, showing a total revenue of 1.187 billion yuan for the first three quarters, a year-on-year decrease of 11.47%, and a net profit of 25.33 million yuan, a year-on-year decrease of 12.36% [2]

证券日报网讯 12月9日，寿仙谷在互动平台回答投资者提问时表示，公司已开始布局国际市场，特别是 在中医药文化认同度较高的东南亚地区。 （文章来源：证券日报） ...

Core Viewpoint - The stock price of Tailong Pharmaceutical (600222) experienced significant volatility after the announcement of a potential change in ownership, initially rising to the limit but then plummeting to a drop limit, ultimately closing down 4.43% on the day of resumption of trading [1][4]. Group 1: Ownership Change - Tailong Pharmaceutical's controlling shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd. (Tairong Investment), is planning to transfer shares, which may lead to a change in control of the company [3][6]. - Tairong Investment intends to transfer 50.1 million shares to Jiang Pharmaceutical Group Jiangxi Medical Holdings Co., Ltd. (Jiang Pharmaceutical Holdings) at a price of 11.043 CNY per share, representing a premium of over 28% compared to the pre-suspension price of 8.58 CNY per share [3][6]. - Following the completion of the transaction, the controlling shareholder will change from Tairong Investment to Jiang Pharmaceutical Holdings, and the actual controller will shift from the Zhengzhou High-tech Industrial Development Zone Management Committee to the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [3][6]. Group 2: Financial Performance - During Tairong Investment's tenure, Tailong Pharmaceutical's performance has been inconsistent, with a revenue increase of 22.2% in 2022, the highest growth since 2018, but a net profit loss [7]. - In the first three quarters of 2024, Tailong Pharmaceutical's revenue declined to 1.187 billion CNY, a year-on-year decrease of 11.47%, and the net profit attributable to shareholders was 25 million CNY, down 12.36% year-on-year [4][7].